The Society of Gynecologic Oncology Annual Meeting on Women’s Cancer | Conference

Jhalak Dholakia, MD, Spotlights Ongoing Trial of Neoadjuvant Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
May 03, 2022

An ongoing trial assessing neoadjuvant mirvetuximab soravtansine plus carboplatin in advanced folate receptor α–positive ovarian was reviewed by Jhalak Dholakia, MD, at The Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.

Catherin Watson, MD, Discusses Designing a Trial on Genetic Testing Education in Ovarian Cancer
April 30, 2022

At SGO 2022, Catherine Watson, MD, spoke about the 2 arms of a randomized education trial presented at the conference.

Ursula A. Matulonis, MD, on the Safety of Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
April 22, 2022

In an interview with CancerNetwork®, Ursula A. Matulonis, MD, discusses the toxicities associated with mirvetuximab soravtansine in folate receptor α–high platinum-resistant ovarian cancer.

Catherin Watson, MD, Talks Genetic Education in Ovarian Cancer
April 20, 2022

At SGO 2022, Catherine Watson, MD, spoke about how to improve genetic education for patients with ovarian cancer.

Marina Frimer, MD, Talks Future Treatments in Uterine Cancer
April 19, 2022

Marina Frimer, MD, spoke about what the future holds for the treatment of patients with platinum-sensitive recurrent uterine cancer.

Ira Winer, MD, PhD, on Surprising Findings From ARTISTRY-1 in Ovarian Cancer
April 15, 2022

Ira Winer, MD, PhD, FACOG, spoke about high response rates observed in patients with pretreated platinum-resistant ovarian cancer from the phase 1/2 ARTISTRY-1 trial.

Ursula A. Matulonis, MD, on Key Findings With Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
April 14, 2022

Ursula A. Matulonis, MD, discusses key data with mirvetuximab soravtansine for patients with folate receptor α–high platinum-resistant ovarian cancer that read out of the phase 3 SORAYA trial.

Jyoti S. Mayadev, MD, on Atezolizumab for Locally Advanced, Node-Positive Cervical Cancer
April 07, 2022

At SGO 2022, Jyoti S. Mayadev, MD presented results of the NRG-GY017 trial of atezolizumab as either an immune primer or with chemoradiation for certain patients with locally advanced cervical cancer.

Ursula A. Matulonis, MD, Highlights the Potential of Mirvetuximab Soravtansine in FRα-High Ovarian Cancer
April 06, 2022

In a discussion with CancerNetwork®, Ursula A. Matulonis, MD, describes the potential of mirvetuximab soravtansine (IMGN853) as a treatment for patients with folate receptor α (FRα)–high platinum-resistant ovarian cancer.

Ira Winer, MD, PhD, Reviews Results of the ARTISTRY-1 Trial in Ovarian Cancer
April 05, 2022

Ira Winer, MD, PhD, FACOG, spoke about patients with pretreated platinum-resistant ovarian cancer treated with nemvaleukin alfa plus pembrolizumab in the phase 1/2 ARTISTRY-1 trial.